People who drink 3-5 cups of coffee per day less likely to develop clogged arteries
the ONA take:
According to a new study published online in the journal Heart, researchers from Kangbuk Samsung Hospital in Seoul, South Korea, have found that people who drink a moderate amount of coffee each day, specifically three to five cups, are less likely to develop clogged arteries that could cause heart attacks.
For the study, researchers sought to investigate the association between coffee consumption and the presence of coronary artery calcium, an early indicator of coronary atherosclerosis.
They analyzed data from a group of 25,138 participants with an average age of 41 years who had no signs of heart disease. All participants attended a health screening examination which included a validated food frequency questionnaire and a multidetector cardiac computed tomography to determine levels of coronary artery calcium.
Results showed that participants who drank three to five cups of coffee per day had the lowest prevalence of clogged arteries, followed by those who drank one to three cups daily, less than one cup, and then those drank at least five cups or more per day compared with non coffee drinkers.
The findings suggest that coffee consumption may be inversely associated with cardiovascular disease risk, but further research is warranted to confirm these findings.
People who drink a moderate amount of coffee each day are less likely to develop clogged arteries that could cause heart attacks.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|